Differences in associations between HSD11B1 gene expression and metabolic parameters in subjects with and without impaired glucose homeostasis

Diabetes Research and Clinical Practice

Volumn 88, Issue 3, 2010, Pages 252-258

  Karlsson, C ^a,b   Jernas M ^a   Olsson, B ^a   Lystig, T ^a,b   Gummesson, A ^a,b   Storlien, L ^c   Groop, L ^d,e   Carlsson, B ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY OF SYDNEY   (Australia)

^d LUND UNIVERSITY DIABETES CENTRE   (Sweden)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

HSD11B1; Metabolic syndrome; Type 2 diabetes

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; MESSENGER RNA; BIOLOGICAL MARKER; HSD11B1 PROTEIN, HUMAN;

ADIPOSE TISSUE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BIOPSY; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LOW CALORY DIET; METABOLIC PARAMETERS; MUSCLE BIOPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; SKELETAL MUSCLE; ANTHROPOMETRY; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION PROFILING; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOSE TISSUE; ANTHROPOMETRY; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION PROFILING; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; OBESITY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 78349300258     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.03.009     Document Type: Article

References (39)

1. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294:2166-2170.
2. Masuzaki H., Yamamoto H., Kenyon C.J., Elmquist J.K., Morton N.M., Paterson J.M., et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 2003, 112:83-90.
3. Paterson J.M., Morton N.M., Fievet C., Kenyon C.J., Holmes M.C., Staels B., et al. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:7088-7093.
4. Kotelevtsev Y., Holmes M.C., Burchell A., Houston P.M., Schmoll D., Jamieson P., et al. 11Beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:14924-14929.
5. Morton N.M., Holmes M.C., Fievet C., Staels B., Tailleux A., Mullins J.J., et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 2001, 276:41293-41300.
6. Morton N.M., Paterson J.M., Masuzaki H., Holmes M.C., Staels B., Fievet C., et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004, 53:931-938.
7. Friedman T.C., Mastorakos G., Newman T.D., Mullen N.M., Horton E.G., Costello R., et al. Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr. J. 1996, 43:645-655.
8. Arnaldi G., Angeli A., Atkinson A.B., Bertagna X., Cavagnini F., Chrousos G.P., et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 2003, 88:5593-5602.
9. Wang M. The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr. Metab. (Lond.) 2005, 2:3.
10. Salehi M., Ferenczi A., Zumoff B. Obesity and cortisol status. Horm. Metab. Res. 2005, 37:193-197.
11. Bujalska I.J., Kumar S., Stewart P.M. Does central obesity reflect " Cushing's disease of the omentum" ?. Lancet 1997, 349:1210-1213.
12. Amelung D., Hubener H.J., Roka L., Meyerheim G. Conversion of cortisone to compound F. J. Clin. Endocrinol. Metab. 1953, 13:1125-1126.
13. Paulmyer-Lacroix O., Boullu S., Oliver C., Alessi M.C., Grino M. Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J. Clin. Endocrinol. Metab. 2002, 87:2701-2705.
14. Rask E., Olsson T., Soderberg S., Andrew R., Livingstone D.E., Johnson O., et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J. Clin. Endocrinol. Metab. 2001, 86:1418-1421.
15. Lindsay R.S., Wake D.J., Nair S., Bunt J., Livingstone D.E., Permana P.A., et al. Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J. Clin. Endocrinol. Metab. 2003, 88:2738-2744.
16. Tomlinson J.W., Moore J.S., Clark P.M., Holder G., Shakespeare L., Stewart P.M. Weight loss increases 11beta-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. J. Clin. Endocrinol. Metab. 2004, 89:2711-2716.
17. Engeli S., Bohnke J., Feldpausch M., Gorzelniak K., Heintze U., Janke J., et al. Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes. Res. 2004, 12:9-17.
18. Jang C., Obeyesekere V.R., Dilley R.J., Krozowski Z., Inder W.J., Alford F.P. Altered activity of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 2007, 92:3314-3320.
19. Tomlinson J.W., Finney J., Gay C., Hughes B.A., Hughes S.V., Stewart P.M. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. Diabetes 2008, 57:2652-2660.
20. Behre C.J., Gummesson A., Jernas M., Lystig T.C., Fagerberg B., Carlsson B., et al. Dissociation between adipose tissue expression and serum levels of adiponectin during and after diet-induced weight loss in obese subjects with and without the metabolic syndrome. Metabolism 2007, 56:1022-1028.
21. Magnusson B., Gummesson A., Glad C.A., Goedecke J.H., Jernas M., Lystig T.C., et al. Cell death-inducing DFF45-like effector C is reduced by caloric restriction and regulates adipocyte lipid metabolism. Metabolism 2008, 57:1307-1313.
22. Gummesson A., Jernas M., Svensson P.A., Larsson I., Glad C.A., Schele E., et al. Relations of adipose tissue CIDEA gene expression to basal metabolic rate, energy restriction, and obesity: population-based and dietary intervention studies. J. Clin. Endocrinol. Metab. 2007, 92:4759-4765.
23. Olofsson L.E., Orho-Melander M., William-Olsson L., Sjoholm K., Sjostrom L., Groop L., et al. CCAAT/enhancer binding protein alpha (C/EBPalpha) in adipose tissue regulates genes in lipid and glucose metabolism and a genetic variation in C/EBPalpha is associated with serum levels of triglycerides. J. Clin. Endocrinol. Metab. 2008, 93:4880-4886.
24. Eriksson K.F., Lindgarde F. Impaired glucose tolerance in a middle-aged male urban population: a new approach for identifying high-risk cases. Diabetologia 1990, 33:526-531.
25. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003, 34:267-273.
26. Rotnitzky A., Jewell N. Hypothesis testing of regression parameters in semiparametric generalized linear models for cluster correlated data. Biometrika 1990, 77:485-497.
27. Palming J., Sjoholm K., Jernas M., Lystig T.C., Gummesson A., Romeo S., et al. The expression of NAD(P)H:quinone oxidoreductase 1 is high in human adipose tissue, reduced by weight loss, and correlates with adiposity, insulin sensitivity, and markers of liver dysfunction. J. Clin. Endocrinol. Metab. 2007, 92:2346-2352.
28. Sjoholm K., Palming J., Lystig T.C., Jennische E., Woodruff T.K., Carlsson B., et al. The expression of inhibin beta B is high in human adipocytes, reduced by weight loss, and correlates to factors implicated in metabolic disease. Biochem. Biophys. Res. Commun. 2006, 344:1308-1314.
29. Zeger S.L., Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986, 42:121-130.
30. Tomlinson J.W., Sinha B., Bujalska I., Hewison M., Stewart P.M. Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J. Clin. Endocrinol. Metab. 2002, 87:5630-5635.
31. Gabrielsson B.G., Olofsson L.E., Sjogren A., Jernas M., Elander A., Lonn M., et al. Evaluation of reference genes for studies of gene expression in human adipose tissue. Obes. Res. 2005, 13:649-652.
32. Rosenstock J., Banarer S., Fonseca V., Inzucchi S., Hollis G.F., Flore R., et al. Efficacy and safety of the 11β-HSD1 inhibitor, INCB13739, added to metformin therapy in patients with type 2 diabetes. American Diabetes Association's 69th Scientific Sessions 2009, (7-LB).
33. Goedecke J.H., Wake D.J., Levitt N.S., Lambert E.V., Collins M.R., Morton N.M., et al. Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. Clin. Endocrinol. (Oxf.) 2006, 65:81-87.
34. Alberti L., Girola A., Gilardini L., Conti A., Cattaldo S., Micheletto G., et al. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects. Int. J. Obes. (Lond.) 2007, 31:1826-1831.
35. Desbriere R., Vuaroqueaux V., Achard V., Boullu-Ciocca S., Labuhn M., Dutour A., et al. 11Beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 2006, 14:794-798.
36. Stimson R.H., Andersson J., Andrew R., Redhead D.N., Karpe F., Hayes P.C., et al. Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans. Diabetes 2009, 58:46-53.
37. Basu R., Basu A., Grudzien M., Jung P., Jacobson P., Johnson M., et al. Liver is the site of splanchnic cortisol production in obese nondiabetic humans. Diabetes 2009, 58:39-45.
38. Kannisto K., Pietilainen K.H., Ehrenborg E., Rissanen A., Kaprio J., Hamsten A., et al. Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J. Clin. Endocrinol. Metab. 2004, 89:4414-4421.
39. Wake D.J., Rask E., Livingstone D.E., Soderberg S., Olsson T., Walker B.R. Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J. Clin. Endocrinol. Metab. 2003, 88:3983-3988.